# ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access

> **NCT07155434** · — · TERMINATED · sponsor: **UltraSight** · enrollment: 36 (actual)

## Conditions studied

- Hypertrophic Cardiomyopathy (HCM)
- Cardiac Imaging
- Echocardiography
- Mavacamten
- Obstructive Cardiomyopathy, Hypertrophic

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07155434
- **Lead sponsor:** UltraSight
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2025-07-25
- **Primary completion:** 2026-02-24
- **Final completion:** 2026-02-24
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** The sponsor terminated the study following an internal review of program priorities.
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07155434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07155434, "ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07155434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*